Ault Alliance Inc (AULT)

[sweetdwilly]

Well I addressed it multiple times however you may not be able to understand what I am writing. So to put it in simple terms as I stated before investing in any stock is risky. However betting in early stage biotech is even riskier. The point of Phase1, phase2 and phase3 trials is to mainly establish efficacy. If efficacy is well proven it leads to great things for a company. So that being said all I know is the drugs potential in the market which you can see on ALZN website. Which I actually provided a link just last night on another message. Never the less NILE is investing very early on. So far the decision is paying off as we are about to step into phase 2 on that particular drug as ALZN has 2 major products in the pipeline of testing. One is behind the other. Never the less ALZN needs to raise capitol in order to do the scientific research. Which phase trials are expensive and go on for long periods of time. As stated in last nights messages it was established it will be a couple years before one of the drugs in the pipeline will even be close to approval. Because trials dont happen overnight. So the bet is risky we are funding an early stage bio company. I know you want instant gratification from investments which as I stated before is not logical at all. It is funny you have never seen an investor pay over market value which tells me you have probably never invested in an early stage biotech company. Which is all good we live and we learn. But however if you know what a marketing partner is? Not sure if you do. It is an existing large cap biotech company that already has drugs in the pipeline and already has access to distribute the drug. Not just distribute it but market it and educate doctors on what it is so the doctors will prescribe it. Doctors are paid incentives in the form of all sorts of gifts to prescribe a new drug and in general a doctor would not know what a new drug is if sales teams weren't teaching them what it is so they can prescribe it. So plenty of marketing partners pay well above market price for biotech companies when they come in as a partner. Rarely does a Biotech get a market partner before phase trials. Meaning the phase trials efficacy will give confidence to a marketing partner and of course shareholders. So for instance if ALZN phase 2 trials come in good then it is a very strong chance they will get a marketing partner to continue to fund them through phase 3 trials, approval and of course bringing the drug to market. ALZN has no profit has no cash flow because they are an early stage Biotech. So if they want to bring the drug to market they have to raise investors who see the drugs potential. So yes NILE is betting early stage on ALZN as I stated in a prior message is very risky. But NILE hired consultants and felt it was worth the risk. So the more cash they have the easier it is for them to complete phase 2. If you look at the 10K they mention when ALZN makes certain MILESTONES now I emphasize that word as it is important. Because as stated above those milestones are what give investors confidence and marketing partners confidence. So as I stated in previous messages if Phase 2 comes in well then there is a very strong chance we get a marketing partner to pay for the completing studies and bringing it to market. I also mentions how Biotechs ebb and flow and the catalyst that move biotech. Now if you dont understand any of the words in these sentences please just let me know which words you need help with and I can further elaborate. So we as NILE are providing ALZN large amount of capital with a bet that ALZN pipeline drugs will make it approval. Because if they do it is billions upon billions of dollars for these drugs once they reach market. So what I am getting at is even paying $5 for a stock trading at $1 is to help them raise the capital needed to make it through trials. Again it isn't a scam but it is risky. Which is why marketing partners get in after some trials because they want to make a more educated bet. So it is common in biotech for an investor or marketing partner to pay way above the trading PPS. to help fund the company because when the drug gets approved they will make way more than they invested over the drugs life of sales. Does that help? NILE